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Department of Surgery/Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands
PAST
Esophagectomy following neoadjuvant chemoradio-
therapy (nCRT) remains standard treatment for patients
with potentially curable locally advanced esophageal can-
cer (EC). In the CROSS study with carboplatin/paclitaxel
and 41.4 Gy/23 9 1.8 Gy, a pathologic complete response
was achieved in 23% and 49% of patients with esophageal
adenocarcinoma (EAC) and squamous cell carcinoma
(ESCC), respectively.1
However, high-aged patients and those with severe
comorbidity are faced with considerable high postoperative
morbidity and mortality.2 In these patients, who are med-
ically unfit for surgery, definitive chemoradiotherapy
(dCRT) would be a good alternative curative-intended
treatment.3 Most studies in the past explored the usefulness
of cisplatin-based regimen according to the RTOG 85-01
landmark study. Recent studies have shown more or less
equal results of carboplatin/paclitaxel-based dCRT. In
contrast with ESCC, data concerning the efficacy of dCRT
in EAC are still lacking. Besides some recommendation,
age and comorbidity are not clearly implemented in current
treatment guideline of patients with EC.4,5
PRESENT
Many elderly patients have multiple age-associated
comorbidities, limiting the use of current combined treat-
ment with either nCRT or dCRT. In our study age
C 75 years and multiple comorbidities were associated
with a higher probability for dCRT. Approximately 78% of
these elderly patients were treated with dCRT.6 The
strongest associations were found for the combination of
hypertension plus diabetes and the combination of cardio-
vascular with pulmonary comorbidity. The results of this
population-based study support the administration of dCRT
in patients with ESCC having at least two comorbidities or
being older than 75 years. This was seen particularly
among those with cardiovascular diseases or previous
malignancies, because their overall survival after dCRT
was comparable to the overall survival for patients after
nCRT plus surgery. However, in operable patients with
locally advanced EAC, the use of nCRT plus surgery was
associated with a better overall survival regardless of age,
number, and type of pretreatment comorbidities.
FUTURE
In a selected group of elderly patients following dCRT,
good results are reported with complete responses
(58–68%) and 2-year survival rates of 36–64% against
acceptable C grade 3 toxicity (24–36%).7 Several studies
have stressed better results with dCRT in ESCC and the use
of carboplatin/paclitaxel regimen with less toxicity and
similar results compared with cisplatin-based dCRT.8,9
As functional rather than chronological older age is
decisive for a proper treatment decision-making, compre-
hensive geriatric assessment is required in
multidisciplinary tumor boards. Moreover, the increased
risk of postoperative treatment-related morbidity and
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mortality in these patients is associated with the frailty
index. Although there is no consensus on the definition of
frailty and standardized cutoff points, comprehensive
frailty testing facilitates an individualized preoperative risk
assessment, while improving clinical outcome.10
Promising strategies are the use of biomarkers in com-
bined chemoimmunotherapy as (neo)adjuvant,11 whereas
improved outcome and less toxicity might be achieved by
up-to-date radiation techniques, including intensity-modu-
lated radiotherapy and proton therapy.12
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